J 2020

The manifestation of oral mucositis in COVID-19 patients: A case-series

RIAD, Abanoub, Islam KASSEM, Mai BADRAH and Miloslav KLUGAR

Basic information

Original name

The manifestation of oral mucositis in COVID-19 patients: A case-series

Authors

RIAD, Abanoub (818 Egypt, guarantor, belonging to the institution), Islam KASSEM (818 Egypt), Mai BADRAH (818 Egypt) and Miloslav KLUGAR (203 Czech Republic, belonging to the institution)

Edition

Dermatologic Therapy, Hoboken, Wiley, 2020, 1396-0296

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30216 Dermatology and venereal diseases

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.851

RIV identification code

RIV/00216224:14110/20:00116797

Organization unit

Faculty of Medicine

UT WoS

000587315600001

Keywords in English

Oral Mucositis; COVID-19
Změněno: 13/1/2021 13:39, Mgr. Tereza Miškechová

Abstract

V originále

We have read with great interest the correspondence of Kahraman et al (2020) on the emergence of oral mucosal changes adjacent to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; hereby we demonstrate the characteristics of 13 laboratoryconfirmed coronavirus disease (COVID-19) patients with oral mucositis according to the CARE guidelines. The referenced patients sought care at our department from April to August 2020 due to generalized pain and soreness within the oral cavity related mainly to nonkeratinized mucosa without a specific cause (Table 1). All included patients had previously undergone polymerase chain reaction (PCR) testing for SARS-CoV-2, which confirmed their infection with a mean cycle threshold (Ct) value of 18.46 ± 3.8 (12-26). Their mean age was 51.08 ± 8.79 (34-62) years old, and eight of them (62.5%) were females. Regarding their COVID-19 symptoms, two patients (15.4%) had persistent fever, four (30.8%) had ageusia, and two (15.4%) had anosmia. The majority of them (69.2%) had a mild course of SARS-CoV-2 infection and were prescribed paracetamol (PCM); contrarily, four patients experienced a moderate course of infection—two patients (15.4%) were prescribed chloroquine and other two (15.4%) were prescribed dexamethasone.